An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia

被引:78
作者
Henderson, DC
Kunkel, L
Nguyen, DD
Borba, CP
Daley, TB
Louie, PM
Freudenreich, O
Cather, C
Evins, AE
Goff, DC
机构
[1] Harvard Univ, Sch Med, Boston, MA USA
[2] Massachusetts Gen Hosp, Schizophrenia Program, Boston, MA 02114 USA
关键词
clozapine; aripiprazole; weight; lipids; schizophrenia;
D O I
10.1111/j.1600-0447.2005.00612.x
中图分类号
R749 [精神病学];
学科分类号
100205 [精神病与精神卫生学];
摘要
Objective: We conducted this 6-week open-label trial to examine the effects of adjunctive aripiprazole in clozapine-treated subjects on weight, lipid and glucose metabolism, as well as positive and negative symptoms of schizophrenia. Method: Ten clozapine-treated subjects received aripiprazole augmentation; eight completed the 6-week trial and two ended at week 4. Eighty percent were male, the mean age was 38.7 +/- 8.9 years and the mean clozapine dose was 455 +/- 83 mg daily. Results: There was a significant decrease in weight (P = 0.003), body mass index (P = 0.004), fasting total serum cholesterol (P = 0.002) and total triglycerides (P = 0.04) comparing baseline to study endpoint. There was no significant change in total Positive and Negative Syndrome Scale scores. Conclusion: This combination may be useful for clozapine-associated medical morbidity and must be studied in placebo-controlled double-blind randomized trials to determine efficacy and safety.
引用
收藏
页码:142 / 147
页数:6
相关论文
共 34 条
[1]
The impact of weight gain on quality of life among persons with schizophrenia [J].
Allison, DB ;
Mackell, JA ;
McDonnell, DD .
PSYCHIATRIC SERVICES, 2003, 54 (04) :565-567
[2]
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[3]
Allison DB, 2001, J CLIN PSYCHIAT, V62, P22
[4]
Mechanisms of metabolic dyslipidemia in insulin resistant states: Deregulation of hepatic and intestinal lipoprotein secretion [J].
Avramoglu, RK ;
Qiu, W ;
Adeli, K .
FRONTIERS IN BIOSCIENCE, 2003, 8 :D464-D476
[5]
5-HT2C receptor agonists as potential drugs for the treatment of obesity [J].
Bickerdike, MJ .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (08) :885-897
[6]
Radioreceptor binding profile of the atypical antipsychotic olanzapine [J].
Bymaster, FP ;
Calligaro, DO ;
Falcone, JF ;
Marsh, RD ;
Moore, NA ;
Tye, NC ;
Seeman, P ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :87-96
[7]
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study [J].
Casey, DE ;
Carson, WH ;
Saha, AR ;
Liebeskind, A ;
Ali, MW ;
Jody, D ;
Ingenito, GG .
PSYCHOPHARMACOLOGY, 2003, 166 (04) :391-399
[8]
Casey DE, 2001, J CLIN PSYCHIAT, V62, P4
[9]
Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate [J].
Fontaine, KR ;
Heo, M ;
Harrigan, EP ;
Shear, CL ;
Lakshminarayanan, M ;
Casey, DE ;
Allison, DB .
PSYCHIATRY RESEARCH, 2001, 101 (03) :277-288
[10]
Measurement of fatigue in cancer patients: Further validation of the Fatigue Symptom Inventory [J].
Hann, DM ;
Denniston, MM ;
Baker, F .
QUALITY OF LIFE RESEARCH, 2000, 9 (07) :847-854